Shots:

• Genome & Company enters into a clinical trial and supply agreement with Merck KGaA and Pfizer to evaluate the safety- tolerability- biological and clinical activities of GEN-001 + Bavencio (avelumab) for multiple cancer indications
• Genome & Company will sponsor the study while Merck KGaA will supply avelumab in P-I/Ib study which is expected to be initiated in 2020 in the US. Both parties will have access to the clinical data
•  GEN-001 is an oral microbiome therapy developed to have immune-modulating activities and has demonstrated synergistic effect with an immune checkpoint inhibitor to suppress the growth of both immune checkpoint inhibitor sensitive and resistant tumor models

Click here ­to­ read full press release/ article 

 Ref: PRNewswire | Image: Merck KGaA